news/AZN/2023.03.01/Astrazeneca : Transparency Directive - Form 6-K.txt

      Transparency Directive
    

      Voting rights and capital
    

      The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 28 February 2023 the issued share capital of AstraZeneca PLC with voting rights is 1,549,833,487 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,549,833,487.
    

      The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
    

      AstraZeneca
    

      AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
    

      Contacts
    

      For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
    

      Adrian Kemp
    

      Company Secretary
    

      AstraZeneca PLC
    
Attachments


            Original Link
          

            Original Document
          

            Permalink
          



Disclaimer
AstraZeneca plc published this content on 01 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2023 18:16:10 UTC.